Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ0113 in healthy subjects
NCT07394452Phase 1Completed
- Sponsor
- Phecda Medicine
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TJ0113 in psoriasis and autoimmune disease, sponsored by Phecda Medicine. Primary endpoints: Treatment-emergent adverse event incidence in SAD study at 12 days and Treatment-emergent adverse event incidence in MAD study at 12 days. Started Aug 2023; status: completed.
02
Drugs
TJ0113
03
Conditions
psoriasisautoimmune disease
Beyond the preview
Go deeper on NCT07394452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394452.